by Raynovich Rod | May 15, 2022 | 2025 Rayno Biopharmaceuticals Portfolio
May 25 -Update-3 ..We will take this little rally after all the turmoil recently. Our Strategy has not changed since January which is to stay with large cap biopharma stocks . We would like to pick some winners among the smaller cap biotech and diagnostics stocks but...
by Raynovich Rod | Apr 11, 2022 | 2025 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-2 4/13 11;36 AM EDT….GSK buys Sierra Oncology (SRRA) for $1.9B https://www.bizjournals.com/sanjose/news/2022/04/13/glaxosmithkline-to-buy-sierra-oncology-for-19b.html?ana=yahoo XBI up 2.48% to $89 handle, ARKG up 2.35%. Large caps lag except REGN up. ABBV...
by Raynovich Rod | Apr 4, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 …4/6 In volatile end of day trading with Tech stocks and the NASDAQ hit hard down 2.2%, healthcare stocks were winners with the XLV up 1.5%. Other sector winners were staples, energy, real estate and utilities. As one pundit put it, ” the FED is...
by Raynovich Rod | Mar 28, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
4/1/22 Blah market but biotech and healthcare holds.Rally at last 30 min. Spec small caps on a green screen with both ARKG and XBI up. We are trading these stocks off a bottom. IWM up 0.9% to $207 level. Gene therapy stocks rallying: CRSP, EDIT, NTLA. Large caps...
by Raynovich Rod | Mar 21, 2022 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
3/25 2:30 p EDT Large cap core holdings near 52 week highs: ABBV, BMY, MRK, REGN, RHHBY, VRTX. Recent trades doing well: EDIT, EVH. Sold MRNA at a small profit. XBI stalled near $90. SMIDs in the red. Vaccines losing ground BNTX, NVAX MRNA. Energy financials and...
by Raynovich Rod | Feb 14, 2022 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 2/25 Broad Rally Includes Materials XLB, Financials XLF and Healthcare XLV. Dow leads up 2.44%.Investors seek safety of large caps with dividends. XLV up 3% to $130.93. IBB up 1% XBI up 0.43%, QQQ up 1.3%. Large cap leaders: UNH and PFE up over 4%, AMGN AZN...
by Raynovich Rod | Feb 1, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 Another Roller Coaster Week helped by AMZN earnings and jobs report.. Healthcare SPDR Sector (XLV) up 1.39% for week, (4.19%) YTD; IBB up 2.08% for week, (14.4%) YTD; XBI up 2.49% for week, (18.9%) YTD. Large cap healthcare stock leaders over 52 weeks: UNH,...
by Raynovich Rod | Jan 31, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 Feb 6 After a little pop up on Friday we have identified a few trades on technicals. We noticed on screening small cap biotechs that about 90% are at the bottom of their 52 week range. From ARKG holdings two trades and former high fliers: PACB and TDOC. Also...
by Raynovich Rod | Jan 23, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 AAPL ignited rally? Either by oversold conditions or good earnings by AAPL and MSFT we have lift -off from the bottom. If your speculative biotech stocks did not go up today you may want to dump it. Our mid-cap focus list saw nice gains except for CRSP. ARKG...
by Raynovich Rod | Jan 17, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
1/22 …More Freefall on Friday Yesterday’s freefall action felt a lot like 2001 when the market was trying to digest the 1999 bubble days.As we have been saying for many months once the momentum slowed stay away from speculative stocks without financial...
